Physician profile
Cherry E Graves
NPI 1033328471
$871.70
in general payments reported to CMS, 2019-2025
15 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $168 · 2023: $146 · 2024: $185 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $220.07 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $88.39 | 2023-2025 | |
| Sage Therapeutics, LLC | $73.80 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $69.12 | 2023-2025 | |
| Ethicon US, LLC | $68.35 | 2025 | Vistaseal |
| Organon LLC | $66.78 | 2021-2024 | Nexplanon |
| Astellas Pharma US INC | $54.45 | 2024-2025 | Veozah |
| Myovant Sciences INC. | $43.26 | 2022 | |
| Sumitomo Pharma America, INC. | $39.70 | 2023 | Myfembree |
| Millicent US INC | $36.06 | 2024-2025 | Femlyv, Femring, Intrarosa |
| Hologic Sales and Service, LLC | $32.08 | 2024 | Myosure Tissue Removal Device |
| Bayer Healthcare Pharmaceuticals INC. | $27.50 | 2022-2023 | |
| Daiichi Sankyo INC. | $18.99 | 2021 | |
| Mylan Pharmaceuticals INC. | $17.52 | 2021 | |
| Merck Sharp & Dohme LLC | $15.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherry Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.